Alex F. Herrera, MD1, Reid W. Merryman, MD2*, Katherine A. Kong, PhD3*, Heather Sun4*, Jennifer R. Brown, MD, PhD5, David C. Fisher, MD6, Matthew S. Davids, MD7, Eric D. Jacobsen, MD6, Caron A. Jacobson, MD7, Haesook T. Kim, PhD8*, Ann S. LaCasce, MD7, German A. Pihan, MD9, Aliyah R Sohani, MD10, Scott J. Rodig, M.D., Ph.D.11, Arnold S. Freedman, MD6, Jerome Ritz, MD12, Malek Faham, MD, PhD3 and Philippe Armand, MD, PhD7
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA
2Department of Medicine, Brigham and Women's Hospital, Boston, MA
3Adaptive Biotechnologies Corp, South San Francisco, CA
4Department of Pathology, Brigham and Women's Hospital, Boston, MA
5Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
6Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
7Dana-Farber Cancer Institute, Boston, MA
8Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology, Boston, MA
9Pathology, BIDMC, Boston, MA
10Department of Pathology, Massachusetts General Hospital, Boston, MA
11Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
12Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA